Novo Nordisk licenses Nanexa coating for long-acting peptide injectables
The exclusive global deal covers up to five programs aimed at monthly or quarterly dosing and is worth as much as €1.165 billion to Nanexa.
TR
By Tom Reyes · Markets Editor
Sep 26 13:19 ETSource: foreignpolicyjournal.com
The wire
- 01Novo Nordisk licensed Nanexa's PharmaShell coating technology for long-acting peptide injectables in obesity, type 2 diabetes and other cardiometabolic conditions, with Nanexa eligible for €615 million in upfront and development and regulatory milestones plus low single-digit royalties.
- 02Monthly or quarterly dosing would change the administration burden and refill cadence clinicians and pharmacies currently manage with weekly incretin injections.
- 03Novo takes full development and commercial responsibility; no programs or timelines were disclosed. The same week, Lilly signed an InnoCare discovery deal worth up to $3.35 billion and Novartis licensed a BoomRay radioligand for up to $900 million.
From the source
Read at foreignpolicyjournal.comEli Lilly (NYSE: LLY), Novo Nordisk And Novartis Bet On Discovery Platforms Over Late-Stage Pipeline Assets
Big pharma’s dealmaking appetite remains strong in 2026, but the strategic logic has shifted decisively toward platform access over outright company acquisitions.
